Aventis Pharma S.a.

Francois Hamy

Patrick Mailliet

Gilles Doerflinger

Francois Clerc

Thomas Caulfield

Chantal Carrez

Odile Angouillant-Boniface

Jean-Louis Mergny

Abdelazize Laoui

Jean-Francois Riou

Stéphanie Deprets

Isabelle Depaty

Manfred Roesner

The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Chemical derivatives and their application as antitelomerase agents

The present invention discloses and claims benzimidazole compounds of formula (I):in which A is aryl or heteroaryl; Ris selected from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH; 1-imidazolyl or SOMe; Ris selected from optionally substituted &#x2014;CO-alkyl, &#x2014;CO-cycloalkyl, &#x2014;CO-aralkyl, &#x2014;CO-aryl, &#x2014;CO-alkoxy, aryl or aralkyl, or &#x2014;CO-amino, CO&#x2014;NHRor CO&#x2014;RRwherein Rand Rare selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.

Substituted benzimidazole compounds and their use for the treatment of cancer

Growing community of inventors

Illzach, France

Francois Hamy